First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M).
Lecia V. Sequist
Consultant or Advisory Role - Boehringer Ingelheim (U); Clovis (U); Merrimack Pharmaceuticals (U)
Research Funding - Clovis
Jean-Charles Soria
No relevant relationships to disclose
Shirish M. Gadgeel
Research Funding - Clovis
Heather A. Wakelee
Research Funding - Clovis
D. Ross Camidge
Consultant or Advisory Role - Clovis (U)
Andrea Varga
No relevant relationships to disclose
Benjamin J. Solomon
Consultant or Advisory Role - AstraZeneca; Boehringer Ingelheim; Clovis; Novartis; Pfizer; Roche
Vassiliki Papadimitrakopoulou
Consultant or Advisory Role - Clovis (U)
Research Funding - Astellas Pharma; AstraZeneca; Bayer; Celgene; Clovis; Merck; Novartis
Sarah S. Jaw-Tsai
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Lisa Caunt
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Paramjit Kaur
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Lindsey Rolfe
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Andrew R. Allen
Employment or Leadership Position - Clovis
Stock Ownership - Clovis
Jonathan Wade Goldman
Honoraria - Clovis
Research Funding - Clovis